WO2023195953 - A FILM COATED TABLET COMPRISING SELEXİPAG

National phase entry is expected:
Publication Number WO/2023/195953
Publication Date 12.10.2023
International Application No. PCT/TR2023/050302
International Filing Date 30.03.2023
Title **
[English] A FILM COATED TABLET COMPRISING SELEXİPAG
[French] COMPRIMÉ PELLICULÉ COMPRENANT DU SELEXİPAG
Applicants **
SANOVEL ILAC SANAYI VE TICARET ANONIM SIRKETI
Inventors
SUNEL, Fatih
ATAK, Fadime Bilgehan
PEHLIVAN AKALIN, Nur
TUNC, Guldeniz
ARI, Busra
Priority Data
2022/005273   05.04.2022   TR
Application details
Total Number of Claims/PCT *
Number of Independent Claims *
Number of Priorities *
Number of Multi-Dependent Claims *
Number of Drawings *
Pages for Publication *
Number of Pages with Drawings *
Pages of Specification *
*
Number of Office Actions *
*
International Searching Authority
*
Recordal of a Change of the Applicant's Name/Address
*
Type of Assignment
*
Applicant's Legal Status
*
*
*
*
*
*
Entry into National Phase under
*
Patent Delivery
*
Translation

* The data is based on automatic recognition. Please verify and amend if necessary.

** IP-Coster compiles data from publicly available sources. If this data includes your personal information, you can contact us to request its removal.

Quotation for National Phase entry

Country StagesTotal
China Filing, Examination, Granting1985
EPO Filing, Examination, Granting9157
Japan Filing, Examination, Granting2029
South Korea Filing, Examination, Granting1870
USA Filing, Examination, Granting4740
MasterCard Visa
Total: 19,781

The term for entry into the National Phase has expired. This quotation is for informational purposes only

Contact Us
Abstract[English] The present invention relates to a film coated tablet comprising selexipag or crystalline polymorph thereof and D-mannitol as a filler, one more filler, and crospovidone as disintegrant. Furthermore, the tablet is obtained using an effective process.[French] La présente invention concerne un comprimé pelliculé comprenant du selexipag ou un polymorphe cristallin de celui-ci et du D-mannitol en tant que charge, une autre charge et de la crospovidone en tant que délitant. En outre, le comprimé est obtenu à l'aide d'un procédé efficace.

Rejoining the server...